Clinical trial
The Impact of FKBP12 on the Prognosis and Sirolimus Administration in Liver Transplantation Recipients With Hepatocellular Carcinoma: A Single-center Retrospective Cohort Study
Name
2018768
Description
The study evaluated the protein expression levels of FK506-binding protein 12 (FKBP12) in hepatocellular carcinoma (HCC) and paracancerous tissues using immunohistochemistry (IHC). This study aimed to determine the role of FKBP12 in the outcome of liver transplantation recipients with HCC, especially those exceeding the Milan criteria. In addition, we explored how sirolimus administration affected LT recipients'prognosis depending on different FKBP12 expression, aiming to provide some advice for clinical sirolimus application after LT.
Trial arms
Trial start
2015-01-01
Estimated PCD
2021-01-01
Trial end
2023-08-01
Status
Completed
Treatment
FKBP12 expression
The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
Arms:
high FKBP12 expression, low FKBP12 expression
Other names:
sirolimus
Size
178
Primary endpoint
Overall survival
2015.1.1-2021.1.1
Eligibility criteria
Inclusion Criteria:
* (1) pathologically confirmed HCC (2) full post-LT follow-up record
Exclusion Criteria:
* (1)sirolimus treatment less than 30 days or after tumor recurrence (2)died within 90 days (3)underwent multiple-organ transplantation
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 178, 'type': 'ACTUAL'}}
Updated at
2024-05-10
1 organization
1 product
3 indications
Organization
First People's Hospital of HangzhouProduct
FKBP12Indication
Hepatocellular CarcinomaIndication
Liver TransplantIndication
Prognosis